Overview

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Status:
Unknown status
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Treatments:
Lobeline